The Need for Antivirals against Covid-19

Please use this identifier to cite or link to this item:
https://osnadocs.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-202103314214
Open Access logo originally created by the Public Library of Science (PLoS)
Full metadata record
DC FieldValueLanguage
dc.creatorSaalbach, Klaus-
dc.date.accessioned2021-03-31T08:42:01Z-
dc.date.available2021-03-31T08:42:01Z-
dc.date.issued2021-03-31T08:42:02Z-
dc.identifier.citationWorking Paper. Universität Osnabrück, Fachbereich 1 - Kultur- und Sozialwissenschaften, Institut für Sozialwissenschaften, Osnabrück 2021-
dc.identifier.urihttps://osnadocs.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-202103314214-
dc.description.abstractRecent findings have shown that the number of small and major Corona virus mutations is steadily increasing. This has major impact on the Corona policy, because the lockdowns are done to mitigate the burden of the pandemic, but they prolong the time-window for the emergence of more aggressive and infectious mutants. This defense paradox may weaken the effect of vaccinations, both for the antibody response and cellular response or may lead in a worst-case scenario to an escape from natural and vaccine-mediated immunity. Antivirals typically affect sensitive procedures and structures in viruses which cannot easily mutate, i.e., are evolutionary much more stable than the surface structures that can be targeted by natural or vaccine-mediated immunity. Big data analyses have identified a larger set of potentially effective substances, but the research on these substances needs to be definitely intensified.eng
dc.rightsAttribution 3.0 Germany*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/*
dc.subjectCovid-19ger
dc.subjectAntiviralseng
dc.subject.ddc000 - Allgemeines, Wissenschaftger
dc.subject.ddc610 - Medizin, Gesundheitger
dc.titleThe Need for Antivirals against Covid-19eng
dc.typeArbeitspapier [workingPaper]ger
Appears in Collections:FB01 - Hochschulschriften

Files in This Item:
File Description SizeFormat 
Workingpaper_Covid_Antivirals_2021_Saalbach.pdf263,88 kBAdobe PDF
Workingpaper_Covid_Antivirals_2021_Saalbach.pdf
Thumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons